Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vicarious Surgical ( (RBOT) ) just unveiled an announcement.
On October 7, 2025, Vicarious Surgical Inc. announced a securities purchase agreement with an institutional investor for a registered direct offering and a concurrent private placement. The company plans to issue shares of its Class A common stock and warrants, expecting to raise approximately $5.9 million. The offering aims to support general corporate purposes, including working capital and research and development. The transaction is expected to close on October 9, 2025, and involves a lock-up agreement for company officers and directors, as well as restrictions on issuing additional shares or entering variable rate transactions for a specified period.
The most recent analyst rating on (RBOT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.
Spark’s Take on RBOT Stock
According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.
Vicarious Surgical’s stock score reflects significant financial challenges as a pre-revenue company with high cash burn, offset by a moderately stable balance sheet. Technical analysis indicates bearish sentiment, compounded by valuation challenges due to negative earnings. While the earnings call showed strategic advancements, supply chain delays and NYSE compliance issues pose risks. Successful clinical trials and improved cash management will be critical for future performance.
To see Spark’s full report on RBOT stock, click here.
More about Vicarious Surgical
Vicarious Surgical Inc., founded in 2014 and headquartered in Waltham, Massachusetts, is a next-generation surgical robotics company. The company is focused on developing innovative robotic technology aimed at enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. Its proprietary technology involves human-like surgical robots designed to perform minimally invasive surgeries, and it has received backing from prominent investors including Bill Gates and Khosla Ventures.
Average Trading Volume: 52,703
Technical Sentiment Signal: Sell
Current Market Cap: $41.13M
For a thorough assessment of RBOT stock, go to TipRanks’ Stock Analysis page.